NASDAQ:HCM

HUTCHMED (HCM) Stock Forecast, Price & News

$15.83

+0.59 (+3.87%)

(As of 09/22/2023 ET)

Compare

Today's Range: $15.55
▼
$16.11
50-Day Range: $12.20
▼
$16.48
52-Week Range: $7.39
▼
$21.28

Volume: 149,072 shs
Average Volume: 100,391 shs
Market Capitalization: $2.76 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $50.00

HUTCHMED MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 215.9% Upside
$50.00 Price Target
Short Interest: Healthy
0.53% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.03) to ($0.57) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.61 out of 5 stars

Medical Sector

720th out of 966 stocks

Pharmaceutical Preparations Industry

331st out of 450 stocks

3.5

Analyst's Opinion

Consensus Rating
HUTCHMED has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $50.00, HUTCHMED has a forecasted upside of 215.9% from its current price of $15.83.
Amount of Analyst Coverage
HUTCHMED has only been the subject of 2 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
0.53% of the outstanding shares of HUTCHMED have been sold short.
Short Interest Ratio / Days to Cover
HUTCHMED has a short interest ratio ("days to cover") of 8.5.
Change versus previous month
Short interest in HUTCHMED has recently decreased by 10.77%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
HUTCHMED does not currently pay a dividend.
Dividend Growth
HUTCHMED does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for HCM.

0.0

News and Social Media Coverage

MarketBeat Follows
Only 1 people have added HUTCHMED to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, HUTCHMED insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.60% of the stock of HUTCHMED is held by insiders.
Percentage Held by Institutions
Only 14.13% of the stock of HUTCHMED is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for HUTCHMED are expected to decrease in the coming year, from ($0.03) to ($0.57) per share.
Price to Book Value per Share Ratio
HUTCHMED has a P/B Ratio of 4.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About HUTCHMED (NASDAQ:HCM) Stock

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; HMPL-A83, an investigational IgG4-type humanized anti-CD47 monoclonal antibody; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.

HCM Price History

30 days | 90 days | 365 days | Advanced Chart

HCM Stock News Headlines

September 12, 2023 | finance.yahoo.com

HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer

August 21, 2023 | msn.com

Hutchmed's Candidate Achieves Main Goal In China's Rare Blood Disorder Study

September 23, 2023 | Behind the Markets (Ad)

[BREAKING] Pentagon to Spend Billions on "Living Missile"

Air Force Magazine calls it "transformational." The Wall Street Journal calls it one of the Pentagon's "highest priorities." National Defense Magazine reports "Eye-popping budget" for it. This small company won the first contract to build them!

August 20, 2023 | markets.businessinsider.com

HUTCHMED : Sovleplenib Phase III ESLIM-01 Study Meets Main Goal In Primary Immune Thrombocytopenia

August 20, 2023 | finance.yahoo.com

HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China

August 13, 2023 | ca.finance.yahoo.com

HCM - HUTCHMED (China) Limited

July 31, 2023 | finanznachrichten.de

HUTCHMED (China) Limited: HUTCHMED Reports 2023 Interim Results and Provides Business Updates

July 31, 2023 | finance.yahoo.com

HUTCHMED Reports 2023 Interim Results and Provides Business Updates

September 23, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

July 19, 2023 | finance.yahoo.com

HUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study

July 13, 2023 | benzinga.com

HUTCHMED Announces Changes to Board of Directors and Technical Committee

July 13, 2023 | finance.yahoo.com

HUTCHMED Announces Changes to Board of Directors and Technical Committee

June 15, 2023 | finance.yahoo.com

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

June 9, 2023 | finance.yahoo.com

HUTCHMED Highlights Presentations for Hematological Malignancy Programs at the 2023 EHA and ICML Meetings

June 6, 2023 | au.finance.yahoo.com

HCM.L - HUTCHMED (China) Limited

May 12, 2023 | finance.yahoo.com

HUTCHMED Announces Board of Directors and Board Committee Membership

May 12, 2023 | finance.yahoo.com

HUTCHMED Announces Board of Directors and Board Committee Membership

May 7, 2023 | seekingalpha.com

Our Update On Hutchmed China's Progress

April 17, 2023 | finance.yahoo.com

HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer

April 11, 2023 | finance.yahoo.com

HUTCHMED Highlights Presentations at American Association for Cancer Research Annual Meeting 2023

April 4, 2023 | finance.yahoo.com

HUTCHMED Initiates Registration Phase Enrollments of HMPL-453 for IHCC and Savolitinib for Gastric Cancer following NMPA Consultations

March 12, 2023 | finance.yahoo.com

HUTCHMED Confirms No Assets Held at Silicon Valley Bank

January 23, 2023 | finance.yahoo.com

HUTCHMED Out Licenses Fruquintinib To Takeda Outside China

January 23, 2023 | markets.businessinsider.com

Takeda To Pay Up To $1.13 Bln To HUTCHMED For Exclusive License Of Fruquintinib Outside China

January 1, 2023 | finance.yahoo.com

HUTCHMED (China) Limited (HCM)

November 14, 2022 | finance.yahoo.com

Hutchmed-Lilly Partnered Gastric Cancer Drug Shows Mixed Results In Phase 3 Study

November 13, 2022 | finance.yahoo.com

HUTCHMED Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China

See More Headlines

Receive HCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HUTCHMED and its competitors with MarketBeat's FREE daily newsletter.

HCM Company Calendar

Today: 9/22/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:HCM
CUSIP: N/A
CIK: 1648257
Web: www.chi-med.com
Phone: 852-2121-3888
Fax: 852-2128-1778
Employees: 2,025
Year Founded: 2000

Price Target and Rating

Average Stock Price Forecast: $50.00
High Stock Price Forecast: $50.00
Low Stock Price Forecast: $50.00
Forecasted Upside/Downside: +215.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.05
Current Ratio: 3.20
Quick Ratio: 3.04

Sales & Book Value

Annual Sales: $426.41 million
Price / Sales: 6.47
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.68 per share
Price / Book: 4.30

Miscellaneous

Outstanding Shares: 174,200,000
Free Float: 167,927,000
Market Cap: $2.76 billion
Optionable: Not Optionable
Beta: 1.01

Social Links

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Chi Keung To ACGI (Age 71)
B.Sc., BSc, M.B.A., MBA, Exec. Chairman
Comp: $85k

Dr. Wei-Guo Su B.Sc. (Age 65)
Ph.D., CEO, Chief Scientific Officer & Exec. Director
Comp: $1.97M

Mr. Chig Fung Cheng BEc (Age 56)
CA, CFO & Exec. Director
Comp: $886k

Ms. Edith Shih BSE (Age 71)
C.S., CGP, EdM, FCIS, FCS, FCS(PE), M.A., MA, Company Sec. & Non-Exec. Director

Dr. Karen Jane Atkin (Age 57)
Exec. VP & COO

Mr. Kin Hung Lee M.B.A. (Age 46)
Sr. VP of Corp. Fin. & Devel.

Mr. Charles George Rupert Nixon (Age 53)
Group Gen. Counsel

Ms. Selina Zhang
Sr. VP of Global HR

Dr. Qingmei Wang Ph.D. (Age 60)
Sr. VP of Bus. Devel. & Strategic Alliances

Mr. Hong Chen (Age 53)
Sr. VP & Chief Commercial Officer- China

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

HCM Stock - Frequently Asked Questions

Should I buy or sell HUTCHMED stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HUTCHMED in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HCM shares.
View HCM analyst ratings or view top-rated stocks.
What is HUTCHMED's stock price forecast for 2023?: 2 analysts have issued 1 year price objectives for HUTCHMED's shares. Their HCM share price forecasts range from $50.00 to $50.00. On average, they expect the company's share price to reach $50.00 in the next year. This suggests a possible upside of 215.9% from the stock's current price.
View analysts price targets for HCM or view top-rated stocks among Wall Street analysts.
How have HCM shares performed in 2023?: HUTCHMED's stock was trading at $14.78 at the beginning of the year. Since then, HCM shares have increased by 7.1% and is now trading at $15.83.
View the best growth stocks for 2023 here.
Are investors shorting HUTCHMED?: HUTCHMED saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 928,000 shares, a decrease of 10.8% from the August 15th total of 1,040,000 shares. Based on an average daily volume of 108,800 shares, the days-to-cover ratio is currently 8.5 days.
View HUTCHMED's Short Interest.
What ETFs hold HUTCHMED's stock?: ETFs with the largest weight of HUTCHMED (NASDAQ:HCM) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Loncar China Biopharma ETF (CHNA).
What other stocks do shareholders of HUTCHMED own?: Based on aggregate information from My MarketBeat watchlists, some companies that other HUTCHMED investors own include Telford Homes (TEF), AbbVie (ABBV), Exelixis (EXEL), GW Pharmaceuticals (GWPH), Premier Oil (PMO), CRISPR Therapeutics (CRSP), AT&T (T), Johnson & Johnson (JNJ), NVIDIA (NVDA) and Weyerhaeuser (WY).

When did HUTCHMED IPO?: (HCM) raised $100 million in an IPO on Thursday, March 17th 2016. The company issued 6,100,000 shares at a price of $16.33 per share. BofA Merrill Lynch and Deutsche Bank Securities acted as the underwriters for the IPO and Stifel, Canaccord Genuity, Panmure Gordon and CITIC CLSA were co-managers.
What is HUTCHMED's stock symbol?: HUTCHMED trades on the NASDAQ under the ticker symbol "HCM."
Who are HUTCHMED's major shareholders?: HUTCHMED's stock is owned by a variety of retail and institutional investors. Top institutional investors include M&G Investment Management Ltd. (4.35%), Schroder Investment Management Group (2.66%), Bellevue Group AG (1.04%), UniSuper Management Pty Ltd (0.33%), Goldman Sachs Group Inc. (0.31%) and State Street Corp (0.25%).
How do I buy shares of HUTCHMED?: Shares of HCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is HUTCHMED's stock price today?: One share of HCM stock can currently be purchased for approximately $15.83.
How much money does HUTCHMED make?: HUTCHMED (NASDAQ:HCM) has a market capitalization of $2.76 billion and generates $426.41 million in revenue each year.
How many employees does HUTCHMED have?: The company employs 2,025 workers across the globe.
How can I contact HUTCHMED?: HUTCHMED's mailing address is 48TH FLOOR CHEUNG KONG CENTER 2 QUEEN`S ROAD CENTRAL, HONG KONG K3, . The official website for the company is www.chi-med.com. The company can be reached via phone at 852-2121-3888, via email at ir@chi-med.com, or via fax at 852-2128-1778.

This page (NASDAQ:HCM) was last updated on 9/23/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial